Day 1 | Day 2 | Day 3 | Download Brochure
Tuesday, February 11
7:00 am Registration and Morning Coffee
9:15 Refreshment Break in the Exhibit Hall with Poster Viewing
10:25 Chairperson’s Remarks
Steven A. Soper, Ph.D., Biomedical Engineering, Chemistry; William H. Pryor Emeritus Professor, Director, Center for BioModular Multi-Scale Systems, University of North Carolina, Chapel Hill
10:30 Single-Cell Analyses Identifying EMT-Related Biomarkers for Metastatic Prostate Cancer
Chun-Liang Chen, Ph.D., Assistant Professor/Research, Molecular Medicine, Institute of Biotechnology, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio
Single-cell approaches are used to study EMT-related markers of CTCs for metastatic prostate cancer detection and prediction. Markers are identified using microfluidics and atomic force microscope (AFM) for molecular profiling and nanomechanical and nanochemical phenotypes of CTCs, respectively.
11:00 Integrated System for the Efficient Analysis of CTC Sub-populations with Divergent Phenotypes
Steven A. Soper, Ph.D., Biomedical Engineering, Chemistry; William H. Pryor Emeritus Professor, Director, Center for BioModular Multi-Scale Systems, University of North Carolina, Chapel Hill; Co-authors Jen Jen Yeh,3,4 George Martin,6 Makgorzata Witek,1 Joyce Kumande,1 Matthew Jackson2 and Mateusz Hupert 1,5, University of North Carolina, Chapel Hill, 1Department of Biomedical Engineering, 2Department of Chemistry, 3Department of Surgery, 4Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, BioFluidica, 5Chapel Hill, NC, 6Roche Molecular Systems Pleasanton, CA
Rare CTC sub-populations can be isolated directly from whole blood using the appropriate markers and processed for molecular signatures to identify key drivers of, for example, epithelial-to-mesenchymal transitions that may be associated with spawning metastatic disease. New microfluidic systems and assays for processing CTC sub-populations and their molecular signatures will be discussed.
11:30 Technology “Show ‘N Tell” Demonstration in the Foyer
The technology “show 'n tell” demonstration will include interactive presentations of novel CTC technologies by the world’s leading researchers. Presenters will showcase prototypes, devices, chips, or movies showing the fabrication or operation of the device in the foyer area. Unlike a poster session, this interactive technology demonstration allows attendees to see the actual technology and get a better understanding of its utility and capabilities.
12:30 pm Session Break
12:40 Luncheon Presentation
Speaker to be Announced
1:10 Luncheon Presentation (Sponsorship Opportunity Available)
1:40 Refreshment Break in the Exhibit Hall with Poster Viewing
2:15 Chairperson’s Remarks
Stefanie Jeffrey, M.D., John & Marva Warnock Professor, Surgery, Chief of Surgical Oncology Research, Stanford University School of Medicine
2:20 The Clinical Application of Circulating Tumor DNA
Luis A. Diaz, M.D., Associate Professor, Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
We developed a dynamic biomarker based on this premise utilizing highly sensitive digital PCR-based and next-generation sequencing-based assays. Ongoing efforts are expanding the role of ctDNA measurements in a variety of clinical scenarios and for the genotyping of patients enrolled in clinical trials. This technology is also being incorporated into the human clinical trials as a companion diagnostic measuring key predictive mutations in the blood.
2:50 Detection of Circulating Tumor DNA by Deep Sequencing
Maximilian Diehn, M.D., Ph.D., Assistant Professor, Radiation Oncology, Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford University
This presentation will discuss detection of circulating tumor DNA using deep sequencing and its potential clinical applications.
3:20 Clinical Utility of Cell-Free DNA/miRNA: Present and Future
David Hoon, MSc, Ph.D., Director, Molecular Oncology, John Wayne Cancer Institute
Cell-free DNA (cfDNA) has evolved into a provocative new approach of assessing genomic and epigenomic alterations in cancer patients' blood. In recent years, cfDNA has been shown to be a potential blood biomarker for monitoring tumor progression.
3:50 Genomic Testing in Oncology: Toward Truly Personalized Cancer Management
Daniel S. Grosu, M.D., MBA, Vice President, Clinical Development & Medical Affairs, Illumina, Inc.
Rapid advances in next-generation sequencing technology are now enabling routine interrogation of tumor genetics on an unprecedented scale. From deep targeted panels to whole genome sequencing, innovative research tools are providing critical new insights into tumor biology, paving the way for earlier diagnosis and more personalized treatment. Emerging methods based on circulating tumor DNA are particularly exciting as they hold the promise of noninvasive tumor detection and characterization, with potential applications across the continuum of cancer care.
4:20 Valentine’s Day Celebration in the Exhibit Hall with Poster Viewing
5:20 Breakout Discussions in the Exhibit Hall
These interactive discussion groups are open to all attendees, speakers, sponsors, & exhibitors. Participants choose a specific breakout discussion group to join. Each group has a moderator to ensure focused discussions around key issues within the topic. This format allows participants to meet potential collaborators, share examples from their work, vet ideas with peers, and be part of a group problem-solving endeavor. The discussions provide an informal exchange of ideas and are not meant to be a corporate or specific product discussion.
Circulating Tumor Cells (CTCs) vs. ctDNA: Which is Best for Liquid Biopsy?
Klaus Pantel, M.D., Professor & Founding Director, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, University of Hamburg
Catherine Alix-Panabières, Ph.D., Maître de Conférence, Praticien Hospitalier, Associate Professor, Director, Laboratory of Rare Human Circulating Cells, Institute of Research in Biotherapy, Saint-Eloi Hospital, University Medical Centre of Montpellier
- Technologies for CTCs and ctDNA detection and characterization
- Potential and limitations of CTCs as Liquid Biopsy
- Potential and limitations of ctDNA as biomarker
- Relationship between CTCs and ctDNA
Exosomes: Research Trends and Diagnostic Potential
Enal Razvi, Ph.D., Biotechnology Analyst
- Research Methodology and Approaches for Exosome Isolation
- Interrogating the Biomarker Cargo in Exosomes
- Potential of Exosomes for Diagnostics
- Current Status of the Field and Drivers of Opportunity
6:30 Close of Day
Day 1 | Day 2 | Day 3 | Download Brochure